04:43 AM EDT, 07/13/2026 (MT Newswires) -- PureTech Health (PRTC.L) said founded entity Celea Therapeutics commenced patient dosing in its late-stage study to evaluate deupirfenidone as a treatment for idiopathic pulmonary fibrosis. The phase 3 Surpass-Ipf trial is assessing the efficacy of deupirfenidone 825 milligrams three times daily, compared with pirfenidone 801 mg with the same daily dose, according to a Monday filing. The primary endpoint of the trial, which expects to enroll 1,100 patients, will be the change from baseline in absolute forced vital capacity. Topline results are expected in the second half of 2029.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.